tetano
Editor, Senior Moderator
Nat Med
. 2023 Mar 23.
doi: 10.1038/s41591-023-02270-2. Online ahead of print.
Maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization
Michal Lipschuetz[SUP] #[/SUP][SUP] 1 2 [/SUP], Joshua Guedalia[SUP] #[/SUP][SUP] 1 [/SUP], Sarah M Cohen[SUP] 1 [/SUP], Yishai Sompolinsky[SUP] 1 [/SUP], Galit Shefer[SUP] 3 [/SUP], Eli Melul[SUP] 3 [/SUP], Zivanit Ergaz-Shaltiel[SUP] 4 [/SUP], Debra Goldman-Wohl[SUP] 1 [/SUP], Simcha Yagel[SUP] 1 [/SUP], Ronit Calderon-Margalit[SUP] 5 [/SUP], Ofer Beharier[SUP] 6 [/SUP]
Affiliations
Abstract
Infants are at a higher risk of Coronavirus Disease 2019 (COVID-19)-related hospitalizations compared to older children. In this study, we investigated the effect of the recommended third maternal dose of BNT162b2 COVID-19 vaccine during pregnancy on rates of infant COVID-19-related hospitalizations. We conducted a nationwide cohort study of all live-born infants delivered in Israel between 24 August 2021 and 15 March 2022 to estimate the effectiveness of the third booster dose versus the second dose against infant COVID-19-related hospitalizations. Data were analyzed for the overall study period, and the Delta and Omicron periods were analyzed separately. Cox proportional hazard regression models estimated hazard ratios and 95% confidence intervals (CIs) for infant hospitalizations according to maternal vaccination status at delivery. Among 48,868 live-born infants included in the analysis, rates of COVID-19 hospitalization were 0.4%, 0.6% and 0.7% in the third-dose, second-dose and unvaccinated groups, respectively. Compared to the second dose, the third dose was associated with reduced infant hospitalization with estimated effectiveness of 53% (95% CI: 36-65%). Greater protection was associated with a shorter interval between vaccination and delivery. A third maternal dose during pregnancy reduced the risk of infant hospitalization for COVID-19 during the first 4 months of life, supporting clinical and public health guidance for maternal booster vaccination to prevent infant COVID-19 hospitalization.
. 2023 Mar 23.
doi: 10.1038/s41591-023-02270-2. Online ahead of print.
Maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization
Michal Lipschuetz[SUP] #[/SUP][SUP] 1 2 [/SUP], Joshua Guedalia[SUP] #[/SUP][SUP] 1 [/SUP], Sarah M Cohen[SUP] 1 [/SUP], Yishai Sompolinsky[SUP] 1 [/SUP], Galit Shefer[SUP] 3 [/SUP], Eli Melul[SUP] 3 [/SUP], Zivanit Ergaz-Shaltiel[SUP] 4 [/SUP], Debra Goldman-Wohl[SUP] 1 [/SUP], Simcha Yagel[SUP] 1 [/SUP], Ronit Calderon-Margalit[SUP] 5 [/SUP], Ofer Beharier[SUP] 6 [/SUP]
Affiliations
- PMID: 36959421
- DOI: 10.1038/s41591-023-02270-2
Abstract
Infants are at a higher risk of Coronavirus Disease 2019 (COVID-19)-related hospitalizations compared to older children. In this study, we investigated the effect of the recommended third maternal dose of BNT162b2 COVID-19 vaccine during pregnancy on rates of infant COVID-19-related hospitalizations. We conducted a nationwide cohort study of all live-born infants delivered in Israel between 24 August 2021 and 15 March 2022 to estimate the effectiveness of the third booster dose versus the second dose against infant COVID-19-related hospitalizations. Data were analyzed for the overall study period, and the Delta and Omicron periods were analyzed separately. Cox proportional hazard regression models estimated hazard ratios and 95% confidence intervals (CIs) for infant hospitalizations according to maternal vaccination status at delivery. Among 48,868 live-born infants included in the analysis, rates of COVID-19 hospitalization were 0.4%, 0.6% and 0.7% in the third-dose, second-dose and unvaccinated groups, respectively. Compared to the second dose, the third dose was associated with reduced infant hospitalization with estimated effectiveness of 53% (95% CI: 36-65%). Greater protection was associated with a shorter interval between vaccination and delivery. A third maternal dose during pregnancy reduced the risk of infant hospitalization for COVID-19 during the first 4 months of life, supporting clinical and public health guidance for maternal booster vaccination to prevent infant COVID-19 hospitalization.